Wedbush Remains Bullish on Carbylan Therapeutics (CBYL) Despite Mixed Cor1.1 Results - PT to $14

Unusual 11 Mid-Day Movers 2/2: (HNSN) (AVXL) (KORS) Higher; (CBYL) (PXLW) (IDTI) Low

Carbylan Therapeutics (Nasdaq: CBYL) 69.0% LOWER; announced top-line results from COR1.1, its first Phase III trial of Hydros-TA for the treatment of pain associated with osteoarthritis of the knee. In the COR1.1 study, Hydros-TA met the first of its two primary endpoints, demonstrating a statistically significant improvement from baseline in the WOMAC A pain score at week 2 versus Hydros (hyaluronic acid alone).

Pixelworks, Inc. (Nasdaq: PXLW) 34.4% LOWER; announced that effective immediately Bruce Walicek has resigned as President and Chief... More

Leerink Partners Downgrades Carbylan Therapeutics (CBYL) to Market Perform

Leerink Partners downgraded Carbylan Therapeutics (NASDAQ: CBYL) from Outperform to Market Perform with a price target of $1.80 (from $15.00).

Analyst Jason Gerberry commented, "We are downgrading CBYL to Market Perform following a disappointing Ph. 3 readout for Hydros-TA in the COR 1.1 trial in which the drug failed to show a stat sig... More

Carbylan Therapeutics's (CBYL) Phase 3 Trial of Hydros-TA in Patients With OA of Knee Meets One Primary Endpoint, Misses Second Primary Endpoint

(Updated - February 1, 2016 5:24 PM EST)

Carbylan Therapeutics (NASDAQ: CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies, today announced top-line results from COR1.1, its first Phase III trial of Hydros-TA for the treatment of pain associated with osteoarthritis of the knee. Hydros-TA is the companys proprietary formulation of hyaluronic acid which entraps a low-dose corticosteroid, triamcinolone acetonide (TA). Hydros contains the same proprietary hyaluronic acid without the addition of TA.

COR1.1 was a 560 patient, international, multi-center, randomized, double-blind study designed to evaluate... More